JonesTrading analyst Soumit Roy reiterated a Buy rating on Infinity Pharma (INFI) today and set a price target of $3.50. The company’s shares closed last Tuesday at $1.52.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 43.2% and a 58.7% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Infinity Pharma with a $3.17 average price target, representing a 69.5% upside. In a report issued on November 9, Oppenheimer also maintained a Buy rating on the stock with a $3.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.85 and a one-year low of $0.60. Currently, Infinity Pharma has an average volume of 554.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
